Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504829 · ClinicalTrials.gov registry record · Phase 2
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
A Phase 2 study of Dyslipidemia, sponsored by Veloxis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT00504829: Completed Phase 2 study of Dyslipidemia, sponsored by Veloxis Pharmaceuticals.
NCT00504829 is a Phase 2 study of Dyslipidemia that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 220 participants, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504829, a Phase 2 study of Dyslipidemia, has completed, sponsored by Veloxis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.
Primary Outcome
Mean percent change from baseline to end-of-treatment (12 weeks) for non-HDL cholesterol and triglycerides and the mean percent change from baseline to end-of-treatment for HDL cholesterol for AtorFen 40/100mg fixed-dose combination tablet versus atorvastatin 40mg tablet.
Conditions Studied
Interventions
- DRUG atorvastatin
- DRUG fenofibrate
- DRUG LCP-AtorFen
Study Locations (1)
Illinois
- Radiant Research, 515 N State Street, Suite 2700 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00504829 record still lists
NCT00504829 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 3 interventions - of which atorvastatin is the first listed.
NCT00504829 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00504829 about?
NCT00504829 is a clinical study titled "Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia". The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.
What is the current status of trial NCT00504829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2007-07. Estimated completion is 2008-07.
What conditions does trial NCT00504829 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT00504829?
The interventions under investigation include: atorvastatin (DRUG), fenofibrate (DRUG), LCP-AtorFen (DRUG).
Who is sponsoring clinical trial NCT00504829?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00504829 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00504829's enrollment target sits among peer trials
220 13th of 40 higher than 28 of 40 other Dyslipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preliminary Study of Safety and Efficacy of Policosanol
COMPLETED · Phase 2
-
Safety Study of BMS-770767 in Subjects With Hypercholesterolemia
COMPLETED · Phase 2
-
Fenofibrate Treatment in SCI
COMPLETED · Phase 2
-
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia